264 related articles for article (PubMed ID: 30578738)
1. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
Lee JH; List A; Sallman DA
Eur J Haematol; 2019 Mar; 102(3):203-209. PubMed ID: 30578738
[TBL] [Abstract][Full Text] [Related]
2. Deletion 5q MDS: molecular and therapeutic implications.
Komrokji RS; Padron E; Ebert BL; List AF
Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
[TBL] [Abstract][Full Text] [Related]
3. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.
Schneider RK; Schenone M; Ferreira MV; Kramann R; Joyce CE; Hartigan C; Beier F; Brümmendorf TH; Germing U; Platzbecker U; Büsche G; Knüchel R; Chen MC; Waters CS; Chen E; Chu LP; Novina CD; Lindsley RC; Carr SA; Ebert BL
Nat Med; 2016 Mar; 22(3):288-97. PubMed ID: 26878232
[TBL] [Abstract][Full Text] [Related]
4. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
Venugopal S; Mascarenhas J; Steensma DP
Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.
Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Capodanno I; Neri A; Morabito F; Vigna E; Gentile M
Eur J Haematol; 2024 Jun; 112(6):860-869. PubMed ID: 38294126
[TBL] [Abstract][Full Text] [Related]
6. 5q- syndrome.
Boultwood J; Pellagatti A; Wainscoat JS
Curr Pharm Des; 2012; 18(22):3180-3. PubMed ID: 22571696
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Gaballa MR; Besa EC
Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
[TBL] [Abstract][Full Text] [Related]
9. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.
Ribezzo F; Snoeren IAM; Ziegler S; Stoelben J; Olofsen PA; Henic A; Ferreira MV; Chen S; Stalmann USA; Buesche G; Hoogenboezem RM; Kramann R; Platzbecker U; Raaijmakers MHGP; Ebert BL; Schneider RK
Leukemia; 2019 Jul; 33(7):1759-1772. PubMed ID: 30651631
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
Adema V; Palomo L; Walter W; Mallo M; Hutter S; La Framboise T; Arenillas L; Meggendorfer M; Radivoyevitch T; Xicoy B; Pellagatti A; Haferlach C; Boultwood J; Kern W; Visconte V; Sekeres M; Barnard J; Haferlach T; Solé F; Maciejewski JP
EBioMedicine; 2022 Jun; 80():104059. PubMed ID: 35617825
[TBL] [Abstract][Full Text] [Related]
11. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
[TBL] [Abstract][Full Text] [Related]
12. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Gorshein E; Weber UM; Gore S
Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
[No Abstract] [Full Text] [Related]
13. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
[TBL] [Abstract][Full Text] [Related]
14. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
Voutsadakis IA; Cairoli A
Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212
[TBL] [Abstract][Full Text] [Related]
15. Genetic deletions in AML and MDS.
Ebert BL
Best Pract Res Clin Haematol; 2010 Dec; 23(4):457-61. PubMed ID: 21130407
[TBL] [Abstract][Full Text] [Related]
16. Dyserythropoiesis of myelodysplastic syndromes.
Lefèvre C; Bondu S; Le Goff S; Kosmider O; Fontenay M
Curr Opin Hematol; 2017 May; 24(3):191-197. PubMed ID: 28072603
[TBL] [Abstract][Full Text] [Related]
17. Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
Buesche G; Teoman H; Schneider RK; Ribezzo F; Ebert BL; Giagounidis A; Göhring G; Schlegelberger B; Bock O; Ganser A; Aul C; Germing U; Kreipe H
Br J Haematol; 2022 Jul; 198(1):114-130. PubMed ID: 35362549
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in the 5q- Syndrome.
Pellagatti A; Boultwood J
Mediterr J Hematol Infect Dis; 2015; 7(1):e2015037. PubMed ID: 26075044
[TBL] [Abstract][Full Text] [Related]
19. A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.
List A; Ebert BL; Fenaux P
Leukemia; 2018 Jul; 32(7):1493-1499. PubMed ID: 29445113
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Talati C; Sallman D; List A
Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]